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Abstract
Background: The incidence of fungaemia has been increasing worldwide. It is important to distinguish non-
Candida fungaemia from candidaemia because of their different antifungal susceptibilities. The aims of this study
were to investigate the clinical characteristics of non-Candida fungaemia and identify the clinical factors that
differentiate it from candidaemia.
Methods: We investigated the clinical manifestations and mortality of non-Candida fungaemia in Kyoto University
Hospital from 2004 to 2009.
Results: There were 110 episodes of fungaemia during the study period. There were 11 renal replacement therapy
episodes of fungaemia due to non-Candida yeasts (10.0%), including 6 episodes with Cryptococcus neoformans, 4
with Trichosporon asahii, and 1 with Kodamaea ohmeri, in addition to 99 episodes of candidaemia (90.0%). The
presence of collagen disease [odds ratio (OR) 9.00; 95% confidence interval (CI) 1.58-51.4; P = 0.01] or renal
replacement therapy (OR 15.0; 95% CI 3.06-73.4; P < 0.01) was significantly more common in non-Candida
fungaemia patients than in candidaemia patients. Prior colonisation by the species may be a predictor of non-
Candida fungaemia. Non-Candida fungaemia had a higher mortality than candidaemia (54.5% versus 21.2%,
P = 0.03).
Conclusions: Although Candida species frequently cause fungaemia, we should also be aware of non-Candida
yeasts because of their high mortality, particularly among high-risk patients, such as those with collagen disease
and those under renal replacement therapy. Prior colonisation by the causative organisms may be an important
predictor of non-Candida fungaemia.
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Background
The incidence of hospital-acquired fungaemia caused by
yeasts has increased dramatically during the past two
decades [1]. This increased incidence has been associ-
ated with advances in clinical medicine, including organ
transplantation, chemotherapy, antimicrobial agents,
parenteral nutrition, and medical devices, all of which
improve patient survival but increase the risk of infec-
tion [2]. Candida species are the leading cause of yeast
fungaemia. However, as the fungaemia patient population
has changed, several types of rare yeasts have become
recognised pathogens, particularly in nosocomial settings,
and have increased in clinical importance [1]. These
yeasts, which include Trichosporon species, Cryptococcus
species, Rhodotorula species, Malassezia species, and
Blastoschizomyces capitatus, have been associated with
life-threatening infections in immunocompromised
patients [3-6].
The mortality rate among patients with fungaemia is
high, ranging from 50% to 80% [1,7-10]. The variable
susceptibility profiles to antifungal agents are one of the
major reasons for the poor prognosis of these yeast
infections. Candida species are usually susceptible to
standard antifungal agents. However, the treatment of
non-Candida yeasts is challenging because of their rarity
and the prevalence of in vitro resistance to standard
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antifungal agents [11]. For example, Cryptococcus species
are resistant to echinocandins, and Trichosporon species
are characterised by resistance to amphotericin and
echinocandins. For these reasons, early distinction
between non-Candida species and Candida species is
important.
Although the importance of non-Candida yeasts is
recognised, little is known about the epidemiology and
risk factors associated with non-Candida fungaemia. To
evaluate the clinical characteristics of non-Candida
fungaemia and determine the risk factors associated with
non-Candida fungaemia, we conducted a retrospective
cohort study of yeast fungaemia detected in a tertiary-care
university hospital over a 6-year period.
Methods
Study population
From 2004 to 2009, all patients with non-Candida
fungaemia were identified through the records of the
clinical microbiological laboratory at Kyoto University
Hospital, a tertiary-care, 1182-bed university hospital in
Japan. The medical records of all patients with yeast
fungaemia were reviewed. Patients were included if they
had evidence of sepsis with at least one positive blood
culture containing yeasts. Only one episode per patient
was included in this study. The Institutional Review Board
of Kyoto University Hospital approved this study protocol.
Clinical characteristics and risk factor analysis
Demographic data, the potential risk factors for develop-
ing yeast fungaemia presenting within 30 days prior to
the diagnosis of fungaemia, and outcomes were retrieved
from the medical records. The following data were
recorded: age, gender, hospital-acquired infection (HAI),
days of hospitalisation prior to the onset of fungaemia,
admission ward at the onset of fungaemia, co-morbidities
(solid malignancy, diabetes mellitus, gastrointestinal/
hepatobiliary disease, chronic kidney disease, haematologic
malignancy, cardiovascular disease, and collagen dis-
ease), underlying conditions [prior intensive care unit
admission, neutropenia, colonisation by the causative
yeast, polymicrobial bacteraemia, assisted ventilation,
renal replacement therapy (haemodialysis and continu-
ous haemodiafiltration), indwelling Foley catheter, cen-
tral venous catheterisation, parenteral nutrition, enteral
nutrition, corticosteroid therapy, chemotherapy, other
immunosuppressant therapy, prior antibiotic therapy,
prior antifungal therapy, prior surgical procedures
(abdominal or other), the severity of illness, and 30-day
mortality.
Species identification and antifungal susceptibility testing
Blood cultures were performed using the BacT/ALERT
automated culture system (bioMerieux, Marcy-l’Etoile,
France). Species identification was performed with
standard laboratory procedures, including morphological
identification and the API 20C AUX system (bioMerieux).
The minimum inhibitory concentrations (MICs) of each
antifungal drug were determined using the reference broth
microdilution method and interpreted according to the
M27-A2 guidelines of the Clinical and Laboratory
Standards Institute [12].
Definitions
HAI was defined as an infection acquired at least
48 hours after hospitalisation that was not clinically
apparent at the time of hospitalisation. Neutropenia was
defined as an absolute neutrophil count of less than 500
cells/μL. Polymicrobial bacteraemia was defined as the
isolation of other bacteria from the blood within
24 hours of the initial positive fungal culture. Fungal
colonisation was defined as a positive culture of causa-
tive yeasts from any bodily site other than blood before
the onset of fungaemia, with no clinical sign or symptom
of infection at that site. Corticosteroid therapy was de-
fined as administration of at least 20 mg of a prednisone
equivalent for at least 1 week (this value was adjusted
according to age for paediatric patients). The severity of
illness was estimated using the sequential organ failure
assessment (SOFA) score on the day of fungaemia onset.
Statistics
Statistical analyses were performed using SPSS version
18.0 (SPSS Inc., Chicago, IL, USA). Fisher’s exact or
Pearson’s chi-square test was used as appropriate to
compare categorical variables. The Mann–Whitney U
test was used to test for the statistical significance of
continuous variables. Multivariate logistic regression
analysis was used for risk factor analysis for non-Candida
fungaemia and outcome analysis. A forward selection
method was used with the entry criterion of a P value
<0.1 for clinical factors associated with risk factors of
non-Candida fungaemia, and factors with a P value
<0.05 were retained in the final model. A P value of
<0.05 was considered statistically significant.
Results
During the study period, 102 yeasts were isolated from
110 patients with fungaemia. No patient had evidence of
human immunodeficiency virus infection. Eleven of 110
episodes (10.0%) were non-Candida fungaemia. Of the
110 episodes of yeast fungaemia, 112 yeast isolates were
identified; 2 of 110 episodes showed coinfection with 2
Candida isolates. Among these yeast isolates, 11 (9.8%)
were non-Candida yeasts, and 101 (90.2%) were
Candida species. Among the 11 non-Candida isolates,
Cryptococcus neoformans (6 isolates, 5.4%), Trichosporon
asahii (4 isolates, 3.6%), and Kodamaea ohmeri (1 isolate,
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0.9%) were identified. Among the 101 Candida isolates,
the most common was Candida albicans (46 isolates,
41.1%), followed by Candida parapsilosis (22 isolates,
19.6%), Candida glabrata (15 isolates, 13.4%), Candida
tropicalis (9 isolates, 8.0%), and Candida guilliermondii
(5 isolates, 4.5%). Candida krusei, Candida lusitaniae,
and Candida famata were isolated in 1 episode each.
Another Candida isolate could not be identified to the
species level.
All 6 C. neoformans isolates showed low MIC values
for amphotericin (0.125-0.25 mg/L) and fluconazole
(1–8 mg/L) and high MIC values for micafungin
(≥32 mg/L). In the 4 isolates of T. asahii, the MIC values
for fluconazole ranged from 4 mg/L to 8 mg/L, and the
MIC values for micafungin were ≥16 mg/L. K. ohmeri
showed low MIC values for amphotericin (0.25 mg/L), flu-
conazole (≤0.125 mg/L), and micafungin (0.25 mg/L).
Nine of the 112 isolates of Candida species were resistant
to fluconazole (8.0%).
The medical records were available for all 110 patients
with fungaemia. Table 1 shows the clinical characteris-
tics of patients with non-Candida fungaemia. Immuno-
suppressants were used in 7 cases (63.6%). Five patients
(45.5%) were under renal replacement therapy. Colonisa-
tion by causative organisms was identified in 8 patients
(72.7%), and urine was the major site of colonisation.
Initial treatment with antifungal agents at a high MIC
was found in 3 of 4 episodes of T. asahii fungaemia.
Two episodes were treated with micafungin, and 1 was
treated with fluconazole. In cryptococcaemia, a lack of
antifungal therapy was identified in 2 cases because
these 2 patients died before starting antifungal therapy,
and others were treated with antifungal agents at a low
MIC. A treatment delay of over 2 days or lack of antifungal
therapy was noted for 8 patients (72.7%).
The demographic characteristics and clinical manifes-
tations of the patients with fungaemia are shown in
Table 2. The median age of non-Candida fungaemia
patients was 66 years (interquartile range 60–71 years),
and 45.5% were female. There was no significant
difference in age (P = 0.80), gender (P = 0.57), frequency
of HAI (P = 0.65), or days of hospitalisation prior to
fungaemia onset (P = 0.62) between the non-Candida
fungaemia and candidaemia groups. Non-Candida
fungaemia had a higher mortality rate than candidaemia
(54.5% versus 21.2%, P = 0.03).
The risk factors in patients with yeast fungaemia are
shown in Table 3. In the univariate analysis, factors
significantly associated with non-Candida fungaemia
were chronic kidney disease [odds ratio (OR) 5.40; 95%
confidence interval (CI) 1.48-19.7; P = 0.01], prior
bacteraemia (OR 3.66; 95% CI 1.00-13.4; P = 0.04), renal
replacement therapy (OR 8.33; 95% CI 2.12-32.8; P < 0.01),
corticosteroid therapy (OR 3.84; 95% CI 1.05-14.1; P =
0.04), and higher SOFA score (OR 1.13; 95% CI 1.03-1.26;
P = 0.02). In the multivariate analysis, independent risk
factors associated with non-Candida fungaemia included
collagen disease (OR 9.00; 95% CI 1.58-51.4; P = 0.01) and
renal replacement therapy (OR 15.0; 95% CI 3.06-73.4;
P < 0.01).
Discussion
Non-Candida yeasts, which are clinically less common
than Candida species, have been associated with life-
threatening infections in immunocompromised individ-
uals. Although the importance of these opportunistic
yeasts is recognised, little is known about their epidemi-
ology [11]. In this study, similar to previous studies,
fungaemia due to non-Candida yeasts was less common
than candidaemia, but it still accounted for a significant
proportion of all fungaemia episodes (10.0%). This inci-
dence was similar to the rate of fluconazole-resistant
Candida among candidaemia in our hospital (8.0%). The
incidence of non-Candida fungaemia was slightly higher
than in previous reports, which have reported rates of
3-6% [2,3]. One possible reason for this finding is that
we included fungaemia caused by C. neoformans in this
study because of its different susceptibility profile to anti-
fungal agents compared to Candida species. Cryptococcus
species are resistant to echinocandins [13]. However,
Table 1 Clinical characteristics of non-Candida fungaemia infection
C. neoformans (n = 6) T. asahii (n = 4) K. ohmeri (n = 1)
Co-morbiditiesa 6 (100%) 4 (100%) 1 (100%)
Immunosuppressant therapy 4(66.7%) 2 (50.0%) 1 (100%)
Renal replacement therapy 2 (33.3%) 2 (50.0%) 1 (100%)
Colonisation by causative yeasts 4 (66.7%) 4 (100%) 1 (100%)
SOFA score, median (range) 9 (1–18) 8 (1–17) 20 (−)
In vitro-active antifungal agent 4 (66.7%) 1 (25.0%) 1 (100%)
30-day mortality 3 (50.0%) 3 (75.0%) 0 (0%)
SOFA: sequential organ failure assessment.
a Co-morbidities of C. neoformans infection include acute respiratory distress syndrome, hepatitis C virus infection, post-living donor liver transplantation (LDLT),
systemic lupus erythaematosus, and miliary tuberculosis. Co-morbidities of T. asahii infection include POEMS syndrome, liver cirrhosis, Bechet’s disease, and acute
myeloid leukaemia. Co-morbidities of K. ohmeri infection include alcoholic liver cirrhosis and post-LDLT.
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Table 2 Demographic characteristics and treatment outcomes of patients with fungaemia (N = 110)
Characteristics Type of fungaemia, N (%) P value
Non-Candida fungaemia Candidaemia Overall
11 (10.0) 99 (90.0) 110 (100)
Age, years a 66 (60–71) 65 (49–74) 65 (54–73) 0.80
Female gender 5 (45.5) 54 (54.5) 59 (53.6) 0.57
Hospital-acquired infection 11 (100) 95 (96.0) 106 (96.4) 0.65
Days of prior hospitalisation a, b 47 (11–66) 30 (12–60) 30 (12–60) 0.62
Admission ward at fungaemia onset 0.71
Surgical ward 3 (27.3) 40 (40.4) 43 (39.1)
Medical ward 6 (54.5) 41 (41.4) 47 (42.7)
ICU 2 (18.2) 14 (14.1) 16 (14.5)
Co-morbidities 11 (100) 92 (92.9) 103 (93.6) 0.47
Solid malignancy 0 (0) 45 (45.5) 45 (40.9) < 0.01*
Diabetes mellitus 5 (45.5) 25 (25.3) 30 (27.3) 0.14
Gastrointestinal/hepatobiliary disease 6 (54.5) 60 (60.6) 66 (60.0) 0.47
Chronic kidney disease 6 (54.5) 18 (18.2) 24 (21.8) 0.01*
Haematologic malignancy 1 (9.1) 14 (14.1) 15 (13.6) 0.54
Cardiovascular disease 3 (27.3) 17 (17.2) 20 (18.2) 0.32
Collagen disease 3 (27.3) 9 (9.1) 12 (10.9) 0.09*
Underlying conditions
Prior ICU admission 5 (45.5) 31 (31.3) 36 (32.7) 0.27
Neutropaenia 1 (9.1) 7 (7.1) 8 (7.3) 0.58
Prior bacteraemia 7 (63.6) 32 (32.3) 39 (35.5) 0.04*
Colonisation by causative yeasts 8 (72.7) 41 (41.4) 49 (44.5) 0.05*
Polymicrobial bacteraemia 5 (45.5) 23 (23.2) 28 (25.5) 0.11
Assisted ventilation 2 (18.2) 17 (17.2) 19 (17.3) 0.60
Renal replacement therapy 5 (45.5) 9 (9.1) 14 (12.7) < 0.01*
Indwelling Foley catheter 7 (63.6) 42 (42.4) 49 (44.5) 0.15
Central venous catheterisation 8 (72.7) 82 (82.8) 90 (8.18) 0.32
Parenteral nutrition 8 (72.7) 80 (80.8) 88 (80.0) 0.38
Enteral nutrition 9 (81.8) 56 (56.6) 65 (59.1) 0.09*
Corticosteroid therapy 7 (63.6) 31 (31.3) 38 (34.5) 0.04*
Chemotherapy 0 (0) 27 (27.3) 27 (24.5) 0.04*
Other immunosuppressant therapy 3 (27.3) 8 (8.1) 11 (10.0) 0.08*
Prior antibiotic therapy 10 (90.9) 89 (89.9) 99 (90.0) 0.70
Prior antifungal therapy 4 (36.4) 18 (18.2) 22 (20.0) 0.15
Prior surgical procedures 2 (18.2) 28 (28.3) 30 (27.3) 0.38
Abdominal surgery 1 (9.1) 19 (19.2) 20 (18.2) 0.37
Other surgery 1 (9.1) 10 (10.1) 11 (10.0) 0.70
SOFA score a 11 (3–17) 3 (1–9) 3.5 (1.8-10) 0.02*
Death within 30 days 6 (54.5) 21 (21.2) 27 (24.5) 0.03*
ICU: intensive care unit; SOFA: sequential organ failure assessment.
Data are presented as median values (interquartile range) for continuous variables and numbers of cases (%) for categorical variables.
P values are marked in bold if <0.05.
a Variables categorised as an ordinal scale in 1-point increments: OR > 1 is the increase in likelihood of the outcome with a 1-point increase in the factor.
b Days of hospitalisation prior to fungaemia onset.
* P < 0.10, variable was included in the multivariate analysis of outcomes from non-Candida fungaemia versus candidaemia.
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micafungin, an echinocandin, is commonly used for initial
empirical therapy for yeast fungaemia in our institute.
Among patients with non-Candida fungaemia, one or
more co-morbidities were identified in all patients, but
none had a solid malignancy. Several factors, including
chronic kidney disease, prior bacteraemia, renal replace-
ment therapy, corticosteroid therapy, higher SOFA
score, and 30-day mortality, were significantly over-
represented in non-Candida fungaemia. However, inde-
pendent risk factors associated with non-Candida
fungaemia only included collagen disease and renal
replacement therapy. Other significant risk factors for
non-Candida fungaemia in the univariate analysis might
have confounded these associations. Although colonisa-
tion by Candida species at multiple sites in the body is
commonly recognised as a major risk factor for invasive
candidiasis in critically ill patients, Candida colonisation
occurs primarily in immunocompromised patients [14].
In this study, colonisation by causative organisms prior
to fungaemia onset was noted in 72.7% of non-Candida
fungaemia patients. This finding is intriguing and may
be an important clue for predicting the occurrence of
non-Candida fungaemia.
Non-Candida fungaemia was significantly associated
with 30-day mortality in the univariate analysis but was
not an independent predictor in the multivariate ana-
lysis. Although this factor could be a confounding vari-
able, the mortality of non-Candida fungaemia was
higher than that of candidaemia (54.5% versus 21.2%).
This high mortality rate is consistent with previous
reports [2,3]. However, the mortality of candidaemia
(21.2%) was lower compared to those of previous reports
(50-80%) [1,7-10]. The difference in the severity of
illness might explain this discrepancy. Anunnatsiri et al.
reported that patients with non-Candida fungaemia and
patients with candidaemia had similar illness severities
[2]. In our study, patients with candidaemia had a lower
SOFA score than patients with non-Candida fungaemia
(P = 0.02), although this difference was not significant in
the multivariate analysis. Another explanation for this
discrepancy is that the clinical intervention by infectious
disease physicians contributed to the low mortality of
candidaemia in our hospital [15].
Inappropriate therapy is a significant predictor of mor-
tality in fungaemia [7,10,16-19]. Antifungal resistance is
common among non-Candida yeasts; thus, treatment
options are limited, and the appropriate therapy can be
left untried [11]. Initial therapy with antifungals at a high
MIC was primarily found in T. asahii fungaemia (75%).
However, the rate of appropriate therapy was similarly
low between non-Candida fungaemia and candidaemia
when appropriate therapy was defined as treatment with
agents at a low MIC within 24 hours (data not shown).
These findings suggest that other factors (e.g., back-
ground and comorbidities) might contribute to the high
mortality of non-Candida fungaemia.
Our results reveal important insights into the epidemi-
ology of non-Candida fungaemia. However, this study had
several limitations. The most important limitation was the
small sample size of non-Candida fungaemia patients
because of low incidence. In addition, other rare oppor-
tunistic yeasts (e.g., Rhodotorula species, Saccharomyces
species, and Malassezia species) were not detected in this
study. Second, due to the retrospective nature of the study,
we did not identify the focus or cause of infection in some
cases; therefore, we could not address the application of
Table 3 Risk factors predicting non-Candida fungaemia
Variables Univariate analysis Multivariate analysis
Crude OR (95% CI) P value Adjusted OR (95% CI) P value
Co-morbidities
Solid malignancy 0.55 (0.46-0.65) < 0.01 - -
Chronic kidney disease 5.40 (1.48-19.7) 0.01 - -
Collagen disease 3.75 (0.84-16.7) 0.09 9.00 (1.58-51.4) 0.01
Underlying conditions
Prior bacteraemia 3.66 (1.00-13.4) 0.04
Colonisation by causative yeasts 3.77 (0.94-15.1) 0.05 - -
Renal replacement therapy 8.33 (2.12-32.8) < 0.01 15.0 (3.06-73.4) < 0.01
Corticosteroid therapy 3.84 (1.05-14.1) 0.04 - -
Chemotherapy 0.73 (0.65-0.82) 0.04 - -
Other immunosuppressant therapy 4.27 (0.94-19.3) 0.08
SOFA score a 1.13 (1.03-1.26) 0.02 - -
OR: odds ratio; SOFA: sequential organ failure assessment.
P values are marked in bold if < 0.05.
a Variables categorised as an ordinal scale in 1-point increments: OR > 1 is the increase in likelihood of the outcome with a 1-point increase in the factor.
P < 0.10, variable was included in the multivariate analysis of outcomes from non-Candida fungaemia versus candidaemia.
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appropriate therapy in all non-Candida fungaemia
patients. Furthermore, we could not carry out molecular
species identification. Finally, this study only evaluated the
crude mortality of patients with fungaemia. The develop-
ment of national databases and well-defined multicentre
studies are needed to resolve these limitations.
Conclusions
In conclusion, although non-Candida fungaemia is a
rare cause of yeast fungaemia, it should receive more
attention because of its high mortality, particularly
among high-risk patients, such as those with collagen
disease and those under renal replacement therapy. Prior
colonisation by causative organisms may be an import-
ant predictor of non-Candida fungaemia.
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